BibTex RIS Cite

GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT

Year 2002, Volume: 15 Issue: 3, 180 - 182, 03.12.2016

Su Gülsün Berrak Ahmet Soysal Emine Türkkan Cengiz Canpolat

Abstract

patient with metastatic Ewing's sarcoma who developed encephalopathy after treatment with gemcitabine, and his rapid recovery after discontinuation of the drug.
Key Words: Gemcitabine, Neurotoxicity, Pediatric cancer

References

  • Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
  • Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35.
  • Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
  • Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
  • Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376.
  • Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
  • Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527.
  • Oelanty N, Vaughan C, Frucht S, Stubgen P.
  • Erythropoe tin-associated hypertensive
  • posterior leukoencephalopathy. Neurology 1997; 49: 686-689.
  • lilion AD, Kallesen J, Cow! CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586- 589.
  • Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cufuroxime-induced encephalopathy. Neurology 1998; 50: 1873-1875.
  • Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-386.

Year 2002, Volume: 15 Issue: 3, 180 - 182, 03.12.2016

Su Gülsün Berrak Ahmet Soysal Emine Türkkan Cengiz Canpolat

Abstract

References

  • Pavlakis N, Bell DH, Millward MJ, et al. Ratal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80: 286-291.
  • Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: S32-S35.
  • Gemzar product labeling. Indianapolis, IN, Eli Lilly and Company, March 1997.
  • Hinchey J, Chaves C, Appignani B, et al. /I reversible posterior leukoencephalopathy syndrome. N Eng! J Med 1996; 334: 494-500.
  • Ay H, Buonannao F, Schaefer F, et al. Posterior leukoencephalopathy without severe hypertension. Utility of diffusion- weighted MRI. Neurology 1998; 51: 1369- 1376.
  • Vaughn D, Jarvik J, Hackney D, el al. High- dose cytarabine neurotoxicity. MR findings during the acute phase. Am J Neuroradiol 1993; 14: 1014-1016.
  • Rontos HA, Wei EP, Deitrich D. Mechanism of cerebral arteriolar abnormalities after acute hypertension. Am J Physiol 1981; 240: 511- 527.
  • Oelanty N, Vaughan C, Frucht S, Stubgen P.
  • Erythropoe tin-associated hypertensive
  • posterior leukoencephalopathy. Neurology 1997; 49: 686-689.
  • lilion AD, Kallesen J, Cow! CT, et al. Ceftazidime-related nonconvulsive status epilepticus. Arch Intern Med 1994; 154: 586- 589.
  • Herishanu YO, Zlotnik M, Mostoslavsky M, et al. Cufuroxime-induced encephalopathy. Neurology 1998; 50: 1873-1875.
  • Jallon P, Fankhauser L, Du Pasquier R, Coeytaux A. Severe but reversible encephalopathy associated with cefepime. Neurophysiol Clin 2000; 30: 383-386.
There are 13 citations in total.

Details

Journal Section Case Reports
Authors

Su Gülsün Berrak This is me

Ahmet Soysal This is me

Emine Türkkan This is me

Cengiz Canpolat This is me

Publication Date December 3, 2016
Published in Issue Year 2002 Volume: 15 Issue: 3

Cite

APA Berrak, S. G., Soysal, A., Türkkan, E., Canpolat, C. (2016). GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Medical Journal, 15(3), 180-182.
AMA Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. March 2016;15(3):180-182.
Chicago Berrak, Su Gülsün, Ahmet Soysal, Emine Türkkan, and Cengiz Canpolat. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal 15, no. 3 (March 2016): 180-82.
EndNote Berrak SG, Soysal A, Türkkan E, Canpolat C (March 1, 2016) GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Medical Journal 15 3 180–182.
IEEE S. G. Berrak, A. Soysal, E. Türkkan, and C. Canpolat, “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”, Marmara Med J, vol. 15, no. 3, pp. 180–182, 2016.
ISNAD Berrak, Su Gülsün et al. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal 15/3 (March 2016), 180-182.
JAMA Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. 2016;15:180–182.
MLA Berrak, Su Gülsün et al. “GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT”. Marmara Medical Journal, vol. 15, no. 3, 2016, pp. 180-2.
Vancouver Berrak SG, Soysal A, Türkkan E, Canpolat C. GEMCITABINE-ASSOCIATED REVERSIBLE ENCEPHALOPATHY A CASE REPORT. Marmara Med J. 2016;15(3):180-2.